Juq-470 - !!exclusive!!

: Often featuring a central protagonist, portrayed here by Sayuri Hayama, interacting with coworkers outside of standard business hours.

If you are attempting to locate concrete details, release notes, or cast information regarding JUQ-470, the following analytical approaches are standard practice: JUQ-470

| Target | Type of inhibition | Reported IC₅₀ (nM) | Relevance in cancer | |--------|-------------------|-------------------|---------------------| | | ATP‑competitive | 12 ± 3 | Drives proliferation in breast, lung, and bladder cancers with FGFR1 amplification. | | VEGFR2 (vascular endothelial growth factor receptor 2) | ATP‑competitive | 18 ± 2 | Critical for angiogenesis; inhibition reduces tumor vascular supply. | | Additional off‑targets | Low‑nanomolar binding to PDGFRβ and c‑KIT (reported in broad kinase panels) | 45–90 | May contribute to broader antitumor activity but raise potential safety signals. | : Often featuring a central protagonist, portrayed here

The sponsor is collaborating with a diagnostics partner to co‑develop a that will be submitted alongside a future New Drug Application (NDA) if Phase II/III data prove favorable. | | Additional off‑targets | Low‑nanomolar binding to